Susan Park Perrine

US Patent:

6403647, Jun 11, 2002

Filed:

Apr 25, 2000

Appl. No.:

09/557384

Inventors:

Susan P. Perrine - Weston MA 02493

Assignee:

Susan P. Perrine - Weston MA

International Classification:

A61K 31185

US Classification:

514575, 514576, 514578, 514563, 514568, 514538, 514629, 514546, 514554, 514507

Abstract:

The invention relates to novel compositions and to methods for the pulsed administration of compositions to a patient or to cells in vitro for the treatment of human blood disorders. Compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia and other blood disorders. The, invention also relates to methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies such as viral-induced tumors, other forms of neoplasia and for expansion of cells for hematopoietic transplantation. Pulsed administration has been shown to be more effective than continuous therapy in patients tested.

US Patent:

6451334, Sep 17, 2002

Filed:

Apr 30, 2001

Appl. No.:

09/845805

Inventors:

Susan P. Perrine - Weston MA 02493

Assignee:

Susan P. Perrine - Weston MA

International Classification:

A61F 200

US Classification:

424423, 424451, 424464, 514538, 514546, 514554

Abstract:

The invention relates to novel compositions and to methods for the pulsed administration of compositions to a patient or to cells in vitro for the treatment of human blood disorders. Compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia, blood loss, and other blood disorders. The invention also relates to methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies and for expansion of cells for hematopoietic transplantation. Pulsed administration has been shown to be more effective than continuous therapy in patients tested.

US Patent:

7265153, Sep 4, 2007

Filed:

Jul 1, 2002

Appl. No.:

10/185745

Inventors:

Douglas V. Faller - Weston MA, US
Susan P. Perrine - Weston MA, US
George Stamatoyannopoulos - Seattle WA, US

International Classification:

A61K 31/19

US Classification:

514557

Abstract:

The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.

US Patent:

7910624, Mar 22, 2011

Filed:

Jun 6, 1995

Appl. No.:

08/470830

Inventors:

Susan P. Perrine - Braintree MA, US
Douglas V. Faller - Braintree MA, US

Assignee:

The Trustees of Boston University - Boston MA

International Classification:

A01N 37/00
A61K 31/33

US Classification:

514557, 514183

Abstract:

The invention relates to compositions containing chemical compounds and compositions containing steel factor which stimulate the expression of hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia and other blood disorders. The invention also relates to methods for administering these compositions to patients and to medical aids for the treatment and prevention of blood and other disorders.

US Patent:

8242172, Aug 14, 2012

Filed:

Jul 14, 2010

Appl. No.:

12/836344

Inventors:

Susan P. Perrine - Weston MA, US

Assignee:

Trustees of Boston University - Boston MA

International Classification:

A61K 31/225
A61K 31/22
A61K 31/19

US Classification:

514547, 514549, 514557

Abstract:

The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.

US Patent:

8618068, Dec 31, 2013

Filed:

Dec 8, 2010

Appl. No.:

12/963490

Inventors:

Susan P Perrine - Weston MA, US
Douglas V Faller - Weston MA, US
Ronald J Berenson - Mercer Island WA, US

Assignee:

Trustees of Boston University - Boston MA
Hemaquest Pharmaceuticals, Inc. - Seattle WA

International Classification:

A61K 31/19
A61K 31/706
A61K 31/4406
A61P 7/06

US Classification:

514 43, 514357, 514557

Abstract:

Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor. Treatment can be continued for at least two weeks.

US Patent:

20010034367, Oct 25, 2001

Filed:

Feb 15, 2001

Appl. No.:

09/783029

Inventors:

Douglas Faller - Weston MA, US
Susan Perrine - Weston MA, US
George Stamatoyannopoulos - Seattle WA, US

International Classification:

A61K031/216
A61K031/22

US Classification:

514/543000, 514/546000

Abstract:

The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.

US Patent:

20080027136, Jan 31, 2008

Filed:

Jul 11, 2007

Appl. No.:

11/827362

Inventors:

Douglas Faller - Weston MA, US
Susan Perrine - Weston MA, US
George Stamatoyannopoulos - Seattle WA, US

International Classification:

A61K 31/215
A61K 31/19
A61P 1/00

US Classification:

514529000, 514557000, 514568000, 514574000

Abstract:

The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.